Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Reversion of metabolic dysfunction-associated steatohepatitis by skeletal muscle-directed FGF21 gene therapy

  • Jimenez, Veronica|||0000-0001-9145-9877
  • Sacristan, Victor|||0000-0003-0356-0356
  • Jambrina Pallarés, Claudia|||0000-0002-9093-5568
  • Jaén Sitges, Maria Luisa|||0000-0002-9188-0810
  • Casaña Lorente, Estefania|||0000-0002-1353-5018
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Marcó, Sara|||0000-0003-3502-5198
  • Molas Laplana, Maria|||0000-0002-3215-515X
  • Garcia, Miquel|||0000-0002-1602-4993
  • Grass Costa, Ignasi|||0000-0002-6917-3271
  • León, Xavier|||0000-0002-8393-2721
  • Elias Puigdomenech, Ivet|||0000-0002-1304-9597
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Elias Bosch, Gemma|||0000-0003-1985-7955
  • Sánchez Clares, Víctor|||0000-0001-8631-9239
  • Vilà, Laia|||0000-0002-1211-5804
  • Casellas Comallonga, Alba|||0000-0003-0203-4733
  • Ferre, Tura|||0000-0001-9713-0829
  • Rodó Morera, Jordi|||0000-0001-8533-2597
  • Carretero i Romay, Ana|||0000-0001-9377-4926
  • Pumarola i Batlle, Martí|||0000-0002-0935-7941
  • Navarro Beltrán, Marc|||0000-0002-9678-6129
  • Andaluz Martínez, Anna|||0000-0001-8097-8110
  • Moll, Xavier|||0000-0002-2992-9361
  • Añor Torres, Sònia|||0000-0002-1099-7698
  • Franckhauser, Sylvie|||0000-0001-5255-1224
  • Vergara, Mercedes|||0000-0002-6971-8657
  • Caixàs i Pedragós, Assumpta|||0000-0001-8472-9189
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
The highly prevalent metabolic dysfunction-associated steatohepatitis (MASH) is associated with liver steatosis, inflammation, and hepatocyte injury, which can lead to fibrosis and may progress to hepatocellular carcinoma and death. New treatment modalities such as gene therapy may be transformative for MASH patients. Here, we describe that one-time intramuscular administration of adeno-associated viral vectors of serotype 1 (AAV1) encoding native fibroblast growth factor 21 (FGF21), a key metabolic regulator, resulted in sustained increased circulating levels of the factor, which mediated long-term (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy

  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Bertolín Gálvez, Joan|||0000-0002-5196-0955
  • Jimenez, Veronica|||0000-0001-9145-9877
  • Jaén Sitges, Maria Luisa|||0000-0002-9188-0810
  • Garcia, Miquel|||0000-0002-1602-4993
  • Pujol i Altarriba, Anna|||0000-0002-3484-598X
  • Vilà, Laia|||0000-0002-1211-5804
  • Sacristan, Victor|||0000-0003-0356-0356
  • Barbon, Elena
  • Ronzitti, Giuseppe
  • Andari, Jihad El
  • Tulalamba, Warut
  • Pham, Quang Hong
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • VandenDriessche, Thierry
  • Chuah, Marinee K.
  • Grimm, Dirk
  • Mingozzi, Federico
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Objective: Pompe disease (PD) is caused by deficiency of the lysosomal enzyme acid α-glucosidase (GAA), leading to progressive glycogen accumulation and severe myopathy with progressive muscle weakness. In the Infantile-Onset PD (IOPD), death generally occurs <1 year of age. There is no cure for IOPD. Mouse models of PD do not completely reproduce human IOPD severity. Our main objective was to generate the first IOPD rat model to assess an innovative muscle-directed adeno-associated viral (AAV) vector-mediated gene therapy. Methods: PD rats were generated by CRISPR/Cas9 technology. The novel highly myotropic bioengineered capsid AAVMYO3 and an optimized muscle-specific promoter in conjunction with a transcriptional cis-regulatory element were used to achieve robust Gaa expression in the entire muscular system. Several metabolic, molecular, histopathological, and functional parameters were measured. Results: PD rats showed early-onset widespread glycogen accumulation, hepato- and cardiomegaly, decreased body and tissue weight, severe impaired muscle function and decreased survival, closely resembling human IOPD. Treatment with AAVMYO3-Gaa vectors resulted in widespread expression of Gaa in muscle throughout the body, normalizing glycogen storage pathology, restoring muscle mass and strength, counteracting cardiomegaly and normalizing survival rate. Conclusions: This gene therapy holds great potential to treat glycogen metabolism alterations in IOPD. Moreover, the AAV-mediated approach may be exploited for other inherited muscle diseases, which also are limited by the inefficient widespread delivery of therapeutic transgenes throughout the muscular system.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Rat models of musculoskeletal lysosomal storage disorders and their role in pre-clinical evaluation of gene therapy approaches

  • Marcó, Sara|||0000-0003-3502-5198
  • Muñoz Forero, Sergio Antonio|||0000-0001-6641-5004
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
  • Jimenez, Veronica|||0000-0001-9145-9877
Mice have been a cornerstone of biomedical research for decades for studying a wide range of biological processes, disease mechanisms, and the assessment of therapies. Moreover, mice present several practical advantages such as small size, low cost and ease of genetic manipulation. While mice offer numerous benefits, for certain disease areas, rat models provide a closer representation of human disease progression, offering better insights for translational research and therapeutic development. This closer resemblance is particularly important for research focusing on diseases involving the cardiovascular and musculoskeletal system. In rats, the pathophysiology of these diseases mirrors the clinical alterations observed in humans. This review focuses on the key phenotypic differences between mouse and rat models of lysosomal storage disorders that specifically manifest with cardiac, skeletal muscle, and bone and joint involvement (Pompe and Danon diseases, and Maroteaux-Lamy and Morquio A syndromes). Furthermore, we discuss the therapeutic potential of various adeno-associated viral vector-mediated gene therapies that have been evaluated in these rat models, highlighting their contributions to advancing treatment options for these debilitating conditions.